Latham, NY

The MS Center of Northeastern New York

Multiple Sclerosis

Sclerosis

Relapsing-Remitting Multiple Sclerosis

Chronic Progressive Multiple Sclerosis

Ocrelizumab

Genentech

Pfizer

Roche

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

The MS Center of Northeastern New York | Latham, NY

Site insights

Work at this site?

Active trials

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)

Trial sponsors